{"id":"long-term-course-of-antiandrogen-drugs","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Erectile dysfunction"},{"rate":null,"effect":"Gynecomastia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased libido"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antiandrogens work by competitively binding to androgen receptors or inhibiting androgen synthesis, thereby reducing the biological activity of testosterone and other androgens. This mechanism is used to suppress androgen-dependent cell growth and proliferation. Long-term courses are typically employed in hormone-sensitive conditions where sustained androgen suppression is therapeutically beneficial.","oneSentence":"Antiandrogen drugs block the effects of androgens (male hormones) by inhibiting androgen receptor signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:23.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer (hormone-sensitive)"},{"name":"Androgen-dependent conditions requiring long-term hormonal suppression"}]},"trialDetails":[{"nctId":"NCT05956639","phase":"PHASE3","title":"Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-06-20","conditions":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rezvilutamide"],"phase":"phase_3","status":"active","brandName":"Long-term course of antiandrogen drugs","genericName":"Long-term course of antiandrogen drugs","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antiandrogen drugs block the effects of androgens (male hormones) by inhibiting androgen receptor signaling. Used for Prostate cancer (hormone-sensitive), Androgen-dependent conditions requiring long-term hormonal suppression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}